Straits Times Index
3,255.80 +16.77 (+0.52%) Nikkei
27,518.25 +41.38 (+0.15%) Hang Seng
19,759.47 +191.78 (+0.98%) FTSE 100
7,471.77 +66.32 (+0.90%) BTC-USD
27,061.94 -730.03 (-2.63%) CMC Crypto 200
589.59 -17.86 (-2.94%)
Takeda Pharmaceutical Company Limited (TKPHF)
| Previous close | 32.74 |
| Open | 32.74 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 32.74 - 32.74 |
| 52-week range | 25.07 - 33.10 |
| Volume | |
| Avg. volume | 59,508 |
| Market cap | 50.895B |
| Beta (5Y monthly) | 0.70 |
| PE ratio (TTM) | 31.12 |
| EPS (TTM) | 1.05 |
| Earnings date | N/A |
| Forward dividend & yield | 1.38 (4.31%) |
| Ex-dividend date | 30 Mar 2023 |
| 1y target est | N/A |
- Business Wire
BioLife Plasma Services Opens its 200th Plasma Donation Center in the U.S.
BANNOCKBURN, Ill., March 27, 2023--BioLife Plasma Services, part of the global biopharmaceutical company Takeda, today announced the opening of its 200th plasma donation center in the United States (U.S.)., with new locations in West Springfield, Mass. and Pearland, Texas. This is an important milestone in BioLife’s broader expansion plans to continue opening centers in the U.S. to address the urgent and growing need for plasma.
- Business Wire
Takeda Announces Positive Results in Phase 2b Study of Investigational TAK-279, an Oral, Once-Daily TYK2 Inhibitor, in People with Moderate-to-Severe Plaque Psoriasis
OSAKA, Japan & CAMBRIDGE, Mass., March 18, 2023--Takeda (TSE:4502/NYSE:TAK) today announced positive results from a Phase 2b clinical trial of TAK-279 (NDI-034858), a highly selective, oral allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate-to-severe plaque psoriasis. The study met its primary and secondary endpoints, with a statistically significant greater proportion of TAK-279 patients achieving Psoriasis Area and Severity Index (PASI) 75, 90 and 100 in the 5mg, 15mg and
- Zacks
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
